CA2256327A1 - Polysaccharide sponges for cell culture and transplantation - Google Patents
Polysaccharide sponges for cell culture and transplantationInfo
- Publication number
- CA2256327A1 CA2256327A1 CA002256327A CA2256327A CA2256327A1 CA 2256327 A1 CA2256327 A1 CA 2256327A1 CA 002256327 A CA002256327 A CA 002256327A CA 2256327 A CA2256327 A CA 2256327A CA 2256327 A1 CA2256327 A1 CA 2256327A1
- Authority
- CA
- Canada
- Prior art keywords
- alginate
- polysaccharide
- sponge
- cells
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/10—Hair or skin implants
- A61F2/105—Skin implants, e.g. artificial skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/122—Foams; Dry foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/60—Materials for use in artificial skin
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J9/00—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
- C08J9/26—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof by elimination of a solid phase from a macromolecular composition or article, e.g. leaching out
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
- C08J2305/02—Dextran; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dispersion Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Heart & Thoracic Surgery (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Zoology (AREA)
- Vascular Medicine (AREA)
- Materials For Medical Uses (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Manufacture Of Porous Articles, And Recovery And Treatment Of Waste Products (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
A polysaccharide sponge characterized by having: (i) an average pore size in the range between about 10 µm to about 300 µm; (ii) an average distance between the pores being the wall thickness of the pores in the range between about 5 µm to about 270 µm; and (iii) an E-modulus of elasticity being a measure of the rigidity of the sponge in the range of about 50 kPa to about 500 kPa.
Claims (40)
1. A polysaccharide sponge characterized by having: (i) an average pore size in the range between about 10 µm to about 300 µm; (ii) an average distance between the pores being the wall thickness of the pores in the range between about 5 µm to about 270 µm; and (iii) an E-modulus of elasticity being a measure of the rigidity of the sponge in the range of about 50 kPa to about 500 kPa.
2. A polysaccharide sponge according to claim 1, wherein said sponge comprises a polysaccharide selected from the group comprising the polyanionic polysaccharides: alginates, gellan, gellan gum, xanthan chitosan, agar, carrageenan and the polycationic polysaccharide: chitosan.
3. A polysaccharide sponge according to claim 1 or claim 2, wherein said sponge comprises an alginate selected from the group of alginates characterised by having: (i) a mannuronic acid (M) residue content in the range of between about 25% and about 65% of total residues; (ii) a guluronic acid (G) residue content in the range of between about 35% and about 75% of total residues; (iii) a M/G ratio of about 1/3 and about 1.86/1;
and (iv) a viscosity of the final alginate solution having 1% w/v alginate, from which the sponge is obtained in the range between about 50 cP to about 800cP.
and (iv) a viscosity of the final alginate solution having 1% w/v alginate, from which the sponge is obtained in the range between about 50 cP to about 800cP.
4. A polysaccharide sponge according to claim 3, wherein said sponge comprises an alginate derived from brown sea algae selected from the group consisting of alginate Protanal TM LF 120 (LF 120) derived from Laminaria hyperborea, alginate Protanal TM LF 20/60 (LF 20/60) derived from Laminaria hyperborea, alginate MVGTM (MVG) derived from Laminaria hyperborea, alginate Pronatal TM HF 120 (HF 120) derived from Laminaria hyperborea, alginate Pronatal TM SF 120 (SF 120) derived from Laminaria hyperborea, alginate Pronatal TM SF 120 RB (SF 120 RB) derived from Laminaria hyperborea, alginate Pronatal TM LF 200 RB (LF
200 RB) delived from Laminaria hyperborea, alginate Manugel TM DMR
(DMB) derived from Laminaria hyperborea, Keltone TM HVCR (HVCR) derived from Macrocystis pyrifera, and Keltone TM LV (LV) derived from MacrocYstis pyrifera.
200 RB) delived from Laminaria hyperborea, alginate Manugel TM DMR
(DMB) derived from Laminaria hyperborea, Keltone TM HVCR (HVCR) derived from Macrocystis pyrifera, and Keltone TM LV (LV) derived from MacrocYstis pyrifera.
5. A polysaccharide sponge according to claim 4, wherein said sponge comprises an alginate selected from the group consisting of said LF 120, LF 20/60 and HVCR.
6. A polysaccharide sponge according to any one of claims 3 to 5, wherein said alginate is used in the form of a sodium alginate solution having a concentration of alginate between about 1% to about 3% w/v to provide an alginate concentration between about 0.1% to about 2% w/v in the final solution from which the sponge is obtained.
7. A polysaccharide sponge according to any one of claims 1 to 5, wherein said sponge further comprises a cross-linking agent selected from the group consisting of the salts of calcium, copper, aluminum, magnesium, strontium, barium, tin, zinc, chromium, organic cations, poly(amino acids), poly(ethyleneimine), poly(vinylamine), poly(allylamine), and polysaccharides.
8. A polysaccharide sponge according to claim 7, wherein said sponge further comprises a cross-linking agent selected from the group consisting of calcium chloride (CaCl2), strontium chloride (SrCl2) and calcium gluconate (Ca-Gl).
9. A polysaccharide sponge according to claim 7 or claim 8, wherein said cross-linker is used in the form of a cross-linker solution having a concentration of cross-linker sufficient to provide a cross-linker concentration between about 0.1% to about 0.3% w/v in the final solution from which the sponge is obtained.
10. A polysaccharide sponge according to any one of claims 1 to 9, wherein said sponge is prepared from a polysaccharide solution with or without the addition of a cross-linker.
11. A polysaccharide sponge according to claim 10, wherein said sponge is an alginate sponge prepared from an alginate solution with or without the addition of a cross-linker and wherein said final alginate solution with or without cross-linker from which said sponge is obtained is selected from the group of final solutions, having concentrations of alginate or alginate and cross-linker, consisting of: (i) LF 120 alginate 1% w/v without cross-linker; (ii) LF 120 alginate 1% w/v and Ca-Gl 0.1% w/v; (iii) LF 120 alginate 1% w/v and Ca-Gl 0.2% w/v; (iv) LF 120 alginate 1% w/v and SrCl2 0.16% w/v; (v) LF 120 alginate 1% w/v and CaCl2 0.1% w/v; (vi) LF
120 alginate 0.5% w/v and Ca-Gl 0.2% w/v; (vii) LF 20/60 alginate 1% w/v and Ca-Gl 0.2% w/v; (viii) HVCR alginate 0.5% w/v and Ca-Gl 0.2% w/v;
and (ix) HVCR alginate 1% w/v and Ca-Gl 0.2% w/v.
120 alginate 0.5% w/v and Ca-Gl 0.2% w/v; (vii) LF 20/60 alginate 1% w/v and Ca-Gl 0.2% w/v; (viii) HVCR alginate 0.5% w/v and Ca-Gl 0.2% w/v;
and (ix) HVCR alginate 1% w/v and Ca-Gl 0.2% w/v.
12. A polysaccharide sponge according to claim 11, wherein said sponge is obtained from a final solution of LF 120 alginate 1% w/v and Ca-Gl cross-linker 0.2% w/v.
13. A polysaccharide sponge according to claim 11, wherein said sponge is obtained from a final solution of HVCR alginate 1% w/v and Ca-Gl cross-linker 0.2% w/v.
14. A polysaccharide sponge according to any one of claims 1 to 13 for use as a matrix, substrate or scaffold for growing mammalian cells in vitro.
15. A polysaccharide sponge according to any one of claims 1 to 13 for use as a matrix, substrate or scaffold for implantation into a patient to replace or repair tissue that has been removed or damaged, wherein said implanted sponge is a substrate, matrix or scaffold for surrounding tissue to invade it, proliferate thereon and replace the damaged or removed tissue, or wherein said implant is an initial substrate for vascularization by the surrounding host tissue and the vascularized implant then serves as a substrate to receive injected cells of choice from the host, or grown in vitro, said injected cells being capable of rapid acclimitization and proliferation on the vascularized sponge to rapidly replace the damaged or removed tissue.
16. A polysaccharide sponge according to any one of claims 1 to 13 for use as an implanted support for therapeutic drug delivery into a desired tissue, said drug delivery being by way of the action of genetically engineered cells or natural cells carried by said sponge and expressing said therapeutic drugs, said cells expressing said drug or expressing regulatory proteins to direct the production of the drug endogenously in said tissue.
17. A polysaccharide sponge according to claim 16, wherein said therapeutic drug expressed by said cells carried in said sponge is a therapeutic protein, wherein said cells express said protein or express regulatory proteins to direct the production of said protein endogenously in the tissue into which said sponge is implanted.
18. A polysaccharide sponge according to any one of claims 1 to 13 for use as a matrix, substrate or scaffold for in vitro culturing of plant cells and algae.
19. A polysaccharide sponge according to any one of claims 1 to 13 for use as a matrix, substrate or scaffold for the delivery to a tissue or organ of genetically engineered viral vectors, non-viral vectors, polymeric microspheres and liposomes all encoding or containing a therapeutic agent for said tissue or organ.
20. A polysaccharide sponge according to any one of claims 1 to 13 for use as a matrix, substrate or scaffold for in vitro fertilization of mammalian oocytes.
21. A polysaccharide sponge according to any one of claims 1 to 13 for use as a matrix, substrate or scaffold for storage of fertilized mammalian oocytes or other mammalian cells cultured in vitro.
22. A polysaccharide sponge according to any one of claims 1 to 13 for use as a matrix, substrate or scaffold for the transplantation of cells grown on or within said sponge in vitro into a tissue of a patient in need of said cells as a result of tissue damage, removal, or dysfunction.
23. A process for producing a polysaccharide sponge according to any one of claims 1-22, comprising:
(a) providing a polysaccharide solution containing about 1% to about 3% w/v polysaccharide in water;
(b) diluting said polysaccharide solution with additional water when desired to obtain a final solution having about 0.5% to about 2% w/v polysaccharide, and subjecting said solution of (a) to gelation, to obtain a polysaccharide gel;
(c) freezing the gel of (b); and (d) drying the frozen gel of (c) to obtain a polysaccharide sponge.
(a) providing a polysaccharide solution containing about 1% to about 3% w/v polysaccharide in water;
(b) diluting said polysaccharide solution with additional water when desired to obtain a final solution having about 0.5% to about 2% w/v polysaccharide, and subjecting said solution of (a) to gelation, to obtain a polysaccharide gel;
(c) freezing the gel of (b); and (d) drying the frozen gel of (c) to obtain a polysaccharide sponge.
24. A process according to claim 23, further comprising the addition of a cross-linker to said polysaccharide solution of (a) during the step of gelation (b), said cross-linker being added in an amount to provide a concentration of cross-linker in the final solution being subjected to gelation of between about 0.1% to about 0.3% w/v.
25. A process according to claim 23 or 24, wherein said polysaccharide solution of (a) is prepared by dissolving the polysaccharide in powdered form in double distilled water in amounts to yield a concentration between about 1% to about 3% w/v polysaccharide in said solution, said polysaccharide solution being mixed in a homogenizer at about 25000 RPM for about 30 minutes at room temperature.
26. A process according to any one of claims 23-25, wherein the gelation step (b) is by intensive stirring of the polysaccharide solution in a homogenizer at about 31800 RPM for about 3 minutes, and wherein when a cross-linker is added to the solution, said cross-linker is added very slowly during said intensive stirring of the polysaccharide solution.
27. A process according to any one of claims 23 to 26, wherein said polysaccharide is an alginate of claim 4.
28. A process according to claim 27, wherein in said process, the final solutions subjected to gelation in step (b) are selected from the group consisting of: (i) LF 120 alginate 1% w/v without cross-linker: (ii) LF 120 alginate 1% w/v and Ca-Gl 0.1% w/v; (iii) LF 120 alginate 1% w/v and Ca-Gl 0.2% w/v; (iv) LF 120 alginate 1% w/v and SrCl2 0.15% w/v; (v) LF 120 alginate 1% w/v and CaCl2 0.1% w/v; (vi) LF 120 alginate 0.6% w/v and Ca-Gl 0.2% w/v; (vii) LF 20/60 alginate 1% w/v and Ca-Gl 0.2% w/v; (viii) HVCR alginate 0.5% w/v and Ca-Gl 0.2% w/v; and (ix) HVCR alginate 1%
w/v and Ca-Gl 0.2% w/v.
w/v and Ca-Gl 0.2% w/v.
29. A process according to any one of claims 23-28 wherein said freezing step (c) is by rapid freezing in a liquid nitrogen bath at about -80°C for about 15 minutes.
30. A process according to any one of claims 23-28 wherein said freezing step (c) is by slow freezing in a freezer at about -18°C for about 8-24 hours.
31. A process according to any one of claims 23-30 wherein said drying step (d) is by lyophilization under conditions of about 0.007 mmHg pressure and at about -60°C.
32. A process according to any one of claims 23-31 wherein the final polysaccharide solution with or without cross-linker is poured into a vessel of desired shape before commencement of the intensive stirring of the gelation step (b), said vessel having a shape that is desired for the shape of the polysaccharide sponge.
33. Use of a polysaccharide sponge according to any one of claims 1-13 as a matrix, substrate or scaffold for the in vitro growth of mammalian cells, plant cells, algae, or for the in vitro fertilization of mammalian oocytes.
34. Use of a polysaccharide sponge according to claim 33 for the in vitro growth of fibroblast cells.
35. Use of a polysaccharide sponge according to claim 33 for the in vitro growth of hepatocytes.
36. Use of a polysaccharide sponge according to any one of claims 1 to 13 as a matrix, substrate or scaffold for implantation into a patient according to any one of claims 15-17.
37. Use of a polysaccharide sponge according to any one of claims 1 to 13 as a matrix, substrate or scaffold for the transplantation of cells grown on said sponge in vitro into a tissue of a patient in need of said cells as a result of tissue damage, removal, or dysfunction.
38. Artificial skin comprising a polysaccharide sponge according to any one of claims 1 to 13 and dermal fibroblast cells grown on said sponge in vitro to the stage wherein said cells are in an active proliferating stage suitable for transplantation to a patient in need of said artificial skin.
39. An artificial organ equivalent comprising a polysaccharide sponge according to any one of claims 1 to 13 and representative cells of said organ, said cells having been grown on said sponge in vitro to the stage wherein said cells are fully active and equivalent to the active cells of said organ, said artificial organ being suitable for transplantation or implantation into a patient in need thereof following organ damage.
removal or dysfunction.
removal or dysfunction.
40. An artificial organ equivalent according to claim 39 being an artificial liver equivalent, wherein said cells grown on said sponge are hepatocytes at a stage in which said hepatocytes are active and function in an equivalent manner to hepatocytes in vivo and are suitable for transplantation or implantation into a patient suffering from liver dysfunction, damage or at least partial removal.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL11837696A IL118376A0 (en) | 1996-05-22 | 1996-05-22 | Polysaccharide sponges for cell culture and transplantation |
IL118376 | 1996-05-22 | ||
PCT/IL1997/000161 WO1997044070A1 (en) | 1996-05-22 | 1997-05-21 | Polysaccharide sponges for cell culture and transplantation |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2256327A1 true CA2256327A1 (en) | 1997-11-27 |
CA2256327C CA2256327C (en) | 2012-07-24 |
Family
ID=11068894
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2256327A Expired - Lifetime CA2256327C (en) | 1996-05-22 | 1997-05-21 | Polysaccharide sponges for cell culture and transplantation |
Country Status (12)
Country | Link |
---|---|
US (3) | US6425918B1 (en) |
EP (1) | EP0901384B1 (en) |
JP (1) | JP2000512666A (en) |
AT (1) | ATE249251T1 (en) |
AU (1) | AU714647B2 (en) |
CA (1) | CA2256327C (en) |
DE (1) | DE69724780T2 (en) |
DK (1) | DK0901384T3 (en) |
ES (1) | ES2206707T3 (en) |
IL (1) | IL118376A0 (en) |
PT (1) | PT901384E (en) |
WO (1) | WO1997044070A1 (en) |
Families Citing this family (116)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2318577B (en) * | 1996-10-28 | 2000-02-02 | Johnson & Johnson Medical | Solvent dried polysaccharide sponges |
WO1999058656A2 (en) * | 1998-05-13 | 1999-11-18 | The Regents Of The University Of Michigan | Sustained dna delivery from structural matrices |
IL124957A0 (en) * | 1998-06-16 | 1999-01-26 | Univ Ben Gurion | Active ingredient delivery systems and devices based on porous matrices |
KR100298846B1 (en) * | 1998-09-24 | 2003-10-22 | 한국원자력연구소 | Artificial skin using neutralized chitosan sponge or mixed chitosan / collagen mixed sponge |
ES2491866T3 (en) * | 1999-11-15 | 2014-09-08 | Piramal Healthcare (Canada) Limited | Temperature-controlled, pH-dependent, self-gelling aqueous biopolymer solution |
DE19957388A1 (en) * | 1999-11-24 | 2001-06-13 | Michael Sittinger | Chondroinductive and implantable substrates for cartilage healing and protection |
DK1294414T3 (en) * | 2000-06-29 | 2006-07-24 | Biosyntech Canada Inc | Preparation and method of healing and regenerating cartilage and other tissues |
US7214371B1 (en) | 2000-09-01 | 2007-05-08 | Ben-Gurion University Of The Negev Research & Development Authority | Tissue engineered biografts for repair of damaged myocardium |
EP1369441A4 (en) * | 2001-01-31 | 2004-12-08 | Seikagaku Kogyo Co Ltd | Crosslinked polysaccharide sponge |
EP1372727B1 (en) * | 2001-04-04 | 2010-09-01 | DelSiTech Oy | Biodegradable carrier and method for preparation thereof |
EP1387670B1 (en) * | 2001-05-11 | 2008-10-15 | Ortho-McNeil-Janssen Pharmaceuticals, Inc. | Immune modulation device for use in animals |
JP2003052395A (en) * | 2001-08-09 | 2003-02-25 | Japan Tissue Engineering:Kk | Method for judging transplantation suitability |
TWI230619B (en) * | 2001-08-16 | 2005-04-11 | Ind Tech Res Inst | Method of crosslinking of porous biodegradable polymers |
JP3770555B2 (en) * | 2001-10-25 | 2006-04-26 | 独立行政法人科学技術振興機構 | Composite biomaterial |
WO2003053216A2 (en) * | 2001-12-06 | 2003-07-03 | University Of Washington | Biodegradable, porous structures useful for growing living tissue, and methods of manufacture |
US20040029266A1 (en) * | 2002-08-09 | 2004-02-12 | Emilio Barbera-Guillem | Cell and tissue culture device |
US20040063206A1 (en) * | 2002-09-30 | 2004-04-01 | Rowley Jon A. | Programmable scaffold and method for making and using the same |
US20040147016A1 (en) * | 2002-09-30 | 2004-07-29 | Rowley Jonathan A. | Programmable scaffold and methods for making and using the same |
KR100539371B1 (en) * | 2002-10-21 | 2005-12-27 | 메디칸(주) | In vitro cultured human preadipocyte for human soft tissue volume replacement with injectable material as a scaffold |
US20040126405A1 (en) * | 2002-12-30 | 2004-07-01 | Scimed Life Systems, Inc. | Engineered scaffolds for promoting growth of cells |
CA2514474C (en) * | 2003-01-30 | 2014-05-06 | Avner Yayon | Freeze-dried fibrin matrices and methods for preparation thereof |
KR100984184B1 (en) * | 2003-03-18 | 2010-09-28 | 에스케이케미칼주식회사 | Alginate sponge and preparation method thereof |
US8007823B2 (en) * | 2003-04-03 | 2011-08-30 | Corporation De L'ecole Polytechnique De Montreal | Microporous articles comprising biodegradable medical polymers, method of preparation thereof and method of use thereof |
JP2006525405A (en) | 2003-05-05 | 2006-11-09 | ベン‐グリオン ユニバーシティ オブ ザ ネゲヴ リサーチ アンド デベロップメント オーソリティ | Injectable cross-linked polymer preparations and their use |
DE10323794A1 (en) * | 2003-05-23 | 2004-12-09 | Dr. Suwelack Skin & Health Care Ag | Process for the production of alginate-containing porous moldings |
JP2005046538A (en) * | 2003-07-31 | 2005-02-24 | Jms Co Ltd | Porous body for medical treatment and method for manufacturing it |
JP5383976B2 (en) * | 2003-09-08 | 2014-01-08 | エフエムシー バイオポリマー エイエス | Gelled biopolymer base foam |
JP2005080927A (en) * | 2003-09-09 | 2005-03-31 | Jms Co Ltd | Production method of medical porous body |
ES2342070T3 (en) | 2003-09-12 | 2010-07-01 | Seikagaku Corporation | PSEUDOESPONJA DE POLISACARIDO. |
US8073538B2 (en) | 2003-11-13 | 2011-12-06 | Cardio Polymers, Inc. | Treatment of cardiac arrhythmia by modification of neuronal signaling through fat pads of the heart |
US20050119704A1 (en) * | 2003-11-13 | 2005-06-02 | Peters Nicholas S. | Control of cardiac arrhythmias by modification of neuronal conduction within fat pads of the heart |
CA2551064A1 (en) * | 2004-01-09 | 2005-07-21 | Yissum Research Development Company Of The Hebrew University Of Jerusale M | Compounds, pharmaceutical compositions and therapeutic methods of preventing and treating diseases and disorders associated with amyloid fibril formation |
US20050272153A1 (en) | 2004-01-27 | 2005-12-08 | Zou Xuenong | Bone tissue engineering by ex vivo stem cells ongrowth into three-dimensional trabecular metal |
US7687619B2 (en) * | 2004-02-05 | 2010-03-30 | Millipore Corporation | Room temperature stable agarose solutions |
WO2005078028A1 (en) * | 2004-02-05 | 2005-08-25 | Millipore Corporation | Method of forming polysaccharide structures |
JP4607522B2 (en) * | 2004-08-31 | 2011-01-05 | 焼津水産化学工業株式会社 | Method for producing polymer complex, polymer complex obtained by the method, and method for culturing animal cells using the polymer complex |
AU2005295927B2 (en) * | 2004-10-12 | 2012-02-02 | Fmc Biopolymer As | Self-gelling alginate systems and uses thereof |
US7514256B2 (en) | 2005-02-11 | 2009-04-07 | Emilio Barbera-Guillem | Bioreactor for selectively controlling the molecular diffusion between fluids |
US9427496B2 (en) | 2005-02-18 | 2016-08-30 | Drexel University | Method for creating an internal transport system within tissue scaffolds using computer-aided tissue engineering |
US20060239956A1 (en) * | 2005-04-26 | 2006-10-26 | Lulu Henson | Preparation and use of hydrogels |
US20060292690A1 (en) * | 2005-06-22 | 2006-12-28 | Cesco Bioengineering Co., Ltd. | Method of making cell growth surface |
US8921109B2 (en) | 2005-09-19 | 2014-12-30 | Histogenics Corporation | Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof |
US9005646B2 (en) | 2005-10-12 | 2015-04-14 | Lifenet Health | Compositions for repair of defects in tissues, and methods of making the same |
US9132208B2 (en) * | 2008-08-07 | 2015-09-15 | Lifenet Health | Composition for a tissue repair implant and methods of making the same |
WO2007070660A2 (en) | 2005-12-13 | 2007-06-21 | President And Fellows Of Harvard College | Scaffolds for cell transplantation |
TWI285100B (en) * | 2005-12-27 | 2007-08-11 | Ind Tech Res Inst | Surface modification of polysaccharide, the modified polysaccharide, and method of culturing and recovery cells using the same |
ATE517645T1 (en) * | 2006-03-01 | 2011-08-15 | Fmc Biopolymer As | JELLILED COMPOSITION |
US20080124372A1 (en) * | 2006-06-06 | 2008-05-29 | Hossainy Syed F A | Morphology profiles for control of agent release rates from polymer matrices |
EP2029727B1 (en) * | 2006-06-16 | 2012-04-11 | FMC Biopolymer AS | Alginate coated, collagen matrix cellular device, preparative methods, and uses thereof. |
BRPI0714386A2 (en) * | 2006-07-14 | 2012-12-25 | Fmc Biopolymer As | hydrogel, bead, methods for producing a hydrogel or bead, for implanting an implantable medical bead or device and cells in a patient, for blocking blood vessels, and for forming a hydrogel, implantable medical device, drug release formulation, contrast or radioopaque material, and, embolic therapeutic composition |
CA2662169C (en) * | 2006-09-08 | 2018-03-20 | Symphony Medical, Inc. | Intramyocardial patterning for global cardiac resizing and reshaping |
US20090012413A1 (en) * | 2006-09-08 | 2009-01-08 | Sabbah Hani N | Cardiac patterning for improving diastolic function |
WO2008045506A2 (en) * | 2006-10-10 | 2008-04-17 | President And Fellows Of Harvard College | Biopolymer structures |
EP2120546B1 (en) * | 2006-12-18 | 2016-09-28 | Ben Gurion University Of The Negev | Scaffolding for tissue regeneration or repair |
WO2008081463A2 (en) * | 2007-01-04 | 2008-07-10 | Hepacore Ltd. | Water soluble reactive derivatives of carboxy polysaccharides and fibrinogen conjugates thereof |
JP2010520766A (en) * | 2007-03-09 | 2010-06-17 | コーニング インコーポレイテッド | Three-dimensional gum matrix for cell culture, production method and method of use |
US20080220526A1 (en) * | 2007-03-09 | 2008-09-11 | Ellison Adam J | Gum coatings for cell culture, methods of manufacture and methods of use |
CA2682160C (en) * | 2007-04-11 | 2017-04-04 | Henry Ford Health System | Cardiac repair, resizing and reshaping using the venous system of the heart |
AU2008266060B2 (en) * | 2007-06-13 | 2013-08-29 | Fmc Corporation | Alginate coated, polysaccharide gel-containing foam composite, preparative methods, and uses thereof |
US9770535B2 (en) | 2007-06-21 | 2017-09-26 | President And Fellows Of Harvard College | Scaffolds for cell collection or elimination |
KR20100063744A (en) * | 2007-08-28 | 2010-06-11 | 에프엠씨 코포레이션 | Delayed self-gelling alginate systems and uses thereof |
IL187707A0 (en) * | 2007-11-27 | 2008-11-03 | Univ Ben Gurion | Alginate scaffold in hepatectomy |
US9370558B2 (en) | 2008-02-13 | 2016-06-21 | President And Fellows Of Harvard College | Controlled delivery of TLR agonists in structural polymeric devices |
CN102006891B (en) | 2008-02-13 | 2017-04-26 | 哈佛学院董事会 | Continuous cell programming devices |
US8668863B2 (en) | 2008-02-26 | 2014-03-11 | Board Of Regents, The University Of Texas System | Dendritic macroporous hydrogels prepared by crystal templating |
US20090259210A1 (en) * | 2008-04-10 | 2009-10-15 | Sabbah Hani N | Method, apparatus and kits for forming structural members within the cardiac venous system |
JP5653342B2 (en) * | 2008-04-24 | 2015-01-14 | メドトロニック,インコーポレイテッド | Cold ionizing radiation sterilization |
EP2310002B1 (en) * | 2008-04-24 | 2016-11-02 | Medtronic, Inc | Protective gel based on chitosan and oxidized polysaccharide |
JP2011518837A (en) * | 2008-04-24 | 2011-06-30 | メドトロニック,インコーポレイテッド | Rehydratable thiolated polysaccharide particles and sponges |
JP5757861B2 (en) * | 2008-04-24 | 2015-08-05 | メドトロニック,インコーポレイテッド | Chitosan-containing protective composition |
JP5711113B2 (en) * | 2008-04-24 | 2015-04-30 | メドトロニック,インコーポレイテッド | Thiolated chitosan gel |
WO2010054325A2 (en) * | 2008-11-07 | 2010-05-14 | Kuehnle Agrosystems, Inc. | Preservation and composition of bioprocess algae for production of lipids, seedstock, and feed |
US8735140B2 (en) * | 2008-11-07 | 2014-05-27 | Kuehnle Agrosystems, Inc. | Preservation and composition of bioprocess algae for production of lipids, seedstock, and feed |
WO2010120749A2 (en) | 2009-04-13 | 2010-10-21 | President And Fellow Of Harvard College | Harnessing cell dynamics to engineer materials |
JP5926180B2 (en) | 2009-07-31 | 2016-05-25 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | Methods of cell programming for tolerogenic therapy |
JP5696149B2 (en) * | 2009-09-10 | 2015-04-08 | エフ エム シー コーポレーションFmc Corporation | Seamless alginate capsules |
EP2542230A4 (en) | 2010-03-05 | 2013-08-28 | Harvard College | Enhancement of skeletal muscle stem cell engrafment by dual delivery of vegf and igf-1 |
US9226524B2 (en) | 2010-03-26 | 2016-01-05 | Philip Morris Usa Inc. | Biopolymer foams as filters for smoking articles |
EP2585053A4 (en) | 2010-06-25 | 2014-02-26 | Harvard College | Co-delivery of stimulatory and inhibitory factors to create temporally stable and spatially restricted zones |
PT2624873T (en) | 2010-10-06 | 2020-03-04 | Harvard College | Injectable, pore-forming hydrogels for materials-based cell therapies |
US9095558B2 (en) | 2010-10-08 | 2015-08-04 | Board Of Regents, The University Of Texas System | Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applications |
WO2012048283A1 (en) | 2010-10-08 | 2012-04-12 | Board Of Regents, The University Of Texas System | One-step processing of hydrogels for mechanically robust and chemically desired features |
WO2012064697A2 (en) | 2010-11-08 | 2012-05-18 | President And Fellows Of Harvard College | Materials presenting notch signaling molecules to control cell behavior |
WO2012140650A2 (en) | 2011-04-12 | 2012-10-18 | Hepacore Ltd. | Conjugates of carboxy polysaccharides with fibroblast growth factors and variants thereof |
WO2012148684A1 (en) | 2011-04-27 | 2012-11-01 | President And Fellows Of Harvard College | Cell-friendly inverse opal hydrogels for cell encapsulation, drug and protein delivery, and functional nanoparticle encapsulation |
ES2878089T3 (en) | 2011-04-28 | 2021-11-18 | Harvard College | Injectable preformed macroscopic three-dimensional scaffolds for minimally invasive administration |
US9675561B2 (en) | 2011-04-28 | 2017-06-13 | President And Fellows Of Harvard College | Injectable cryogel vaccine devices and methods of use thereof |
EP2714073B1 (en) | 2011-06-03 | 2021-03-10 | President and Fellows of Harvard College | In situ antigen-generating cancer vaccine |
US9765205B2 (en) | 2011-08-24 | 2017-09-19 | Algix, Llc | Macrophyte-based bioplastic |
WO2013031030A1 (en) | 2011-09-01 | 2013-03-07 | L'oreal | Cosmetic sheet |
ES2773895T3 (en) | 2012-04-16 | 2020-07-15 | Harvard College | Mesoporous Silica Compositions to Modulate Immune Responses |
US11565027B2 (en) | 2012-12-11 | 2023-01-31 | Board Of Regents, The University Of Texas System | Hydrogel membrane for adhesion prevention |
US10500226B2 (en) * | 2012-12-30 | 2019-12-10 | Hadasit Medical Research Services And Development Ltd. | Alginate compositions and uses thereof |
WO2014169250A1 (en) * | 2013-04-11 | 2014-10-16 | President And Fellows Of Harvard College | Prefabricated alginate-drug bandages |
US20160151286A1 (en) * | 2013-05-29 | 2016-06-02 | Therakine Biodelivery Gmbh | Hydrophilic Microparticles, Drug-Delivery Material, Method For Manufacturing Thereof And Methods For Delivery of A Drug-Delivery Composition |
MX2015017235A (en) | 2013-06-13 | 2017-05-04 | Orgenesis Ltd | Cell populations, methods of transdifferention and methods of use thereof. |
EP3137105A4 (en) | 2014-04-30 | 2017-12-27 | President and Fellows of Harvard College | Combination vaccine devices and methods of killing cancer cells |
CN104001213B (en) * | 2014-05-07 | 2016-06-29 | 广州贝奥吉因生物科技有限公司 | A kind of cartilage tissue engineered porous support and preparation method thereof |
US10077420B2 (en) | 2014-12-02 | 2018-09-18 | Histogenics Corporation | Cell and tissue culture container |
MA41296A (en) | 2014-12-30 | 2017-11-07 | Orgenesis Ltd | TRANSDIFFERENTIATION PROCESSES AND METHODS FOR USING THE SAME |
EP3250250A4 (en) | 2015-01-30 | 2019-05-22 | President and Fellows of Harvard College | Peritumoral and intratumoral materials for cancer therapy |
CN107708756A (en) | 2015-04-10 | 2018-02-16 | 哈佛学院院长等 | Immunocyte acquisition equipment and its preparation and application |
FR3039555B1 (en) | 2015-07-30 | 2017-08-18 | Univ Toulouse Iii - Paul Sabatier | PROCESS FOR PREPARING BIOCOMPATIBLE POLYMERIC AND BIODEGRADABLE THREE-DIMENSIONAL MATRICES AND APPLICATIONS |
CN105169473B (en) * | 2015-10-19 | 2018-06-29 | 东南大学 | A kind of ultra-fine hole hydrogel scaffold and preparation method thereof |
EP3400074B1 (en) | 2016-01-07 | 2021-10-20 | B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University | Compositions for generating immunotolerant responses |
EP3411475A4 (en) | 2016-02-06 | 2019-09-11 | President and Fellows of Harvard College | Recapitulating the hematopoietic niche to reconstitute immunity |
AU2017295704B2 (en) | 2016-07-13 | 2023-07-13 | President And Fellows Of Harvard College | Antigen-presenting cell-mimetic scaffolds and methods for making and using the same |
US10821200B2 (en) * | 2016-12-05 | 2020-11-03 | Hyalo Technologies, LLC | Method of sterilization of microparticles |
EP3635106A4 (en) | 2017-05-08 | 2021-01-06 | Orgenesis Ltd. | Transdifferentiated cell populations and methods of use thereof |
CN108853570B (en) * | 2018-07-16 | 2021-04-27 | 浦易(上海)生物技术有限公司 | Hemostatic sponge and preparation method thereof |
US11661576B2 (en) | 2019-02-05 | 2023-05-30 | Corning Incorporated | Packed-bed bioreactor systems and methods of using the same |
US11118151B2 (en) | 2019-11-05 | 2021-09-14 | Corning Incorporated | Fixed bed bioreactor and methods of using the same |
KR102396513B1 (en) * | 2019-12-30 | 2022-05-10 | 조선대학교 산학협력단 | Composition for increasing gamma-amino butyric acid content of mushroom |
CA3165835A1 (en) * | 2020-01-13 | 2021-07-22 | The Regents Of The University Of California | Devices and methods for high-stability supercooling of aqueous media and biological matter |
JP7274041B2 (en) * | 2020-03-17 | 2023-05-15 | 日本たばこ産業株式会社 | Porous body manufacturing method and porous body |
CN115666492A (en) | 2020-04-30 | 2023-01-31 | 莱雅公司 | Skin care kit |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3653383A (en) * | 1969-07-30 | 1972-04-04 | Freeze Dry Products | Algin sponge and process therefor |
FR2167329A1 (en) | 1972-01-13 | 1973-08-24 | Freeze Dry Products | Water-absorbent porous algin sponges - readily disposable for medical uses |
JPS5571537A (en) * | 1978-11-24 | 1980-05-29 | Shin Etsu Chem Co Ltd | Method of manufacturing sponge-like molded body |
US4412947A (en) * | 1979-09-12 | 1983-11-01 | Seton Company | Collagen sponge |
JPS5658469A (en) * | 1979-10-19 | 1981-05-21 | Yoshinari Masuyama | Molding method of glucomannan flour |
DE2943520C2 (en) * | 1979-10-27 | 1982-05-19 | Fa. Carl Freudenberg, 6940 Weinheim | Process for the production of collagen sponge for medical or cosmetic purposes |
US4522753A (en) * | 1980-07-17 | 1985-06-11 | Massachusetts Institute Of Technology | Method for preserving porosity in porous materials |
US4578067A (en) * | 1982-04-12 | 1986-03-25 | Alcon (Puerto Rico) Inc. | Hemostatic-adhesive, collagen dressing for severed biological surfaces |
GB2148901A (en) * | 1983-10-04 | 1985-06-05 | Johnson & Johnson | Protein/polysaccharide complexes |
US4515637A (en) * | 1983-11-16 | 1985-05-07 | Seton Company | Collagen-thrombin compositions |
US5510254A (en) * | 1986-04-18 | 1996-04-23 | Advanced Tissue Sciences, Inc. | Three dimensional cell and tissue culture system |
US5219361A (en) * | 1988-09-16 | 1993-06-15 | Clemson University | Soft tissue implant with micron-scale surface texture to optimize anchorage |
US5602026A (en) * | 1988-10-14 | 1997-02-11 | The General Hospital Corporation | Culturing liver cells between two supports |
EP0585368B1 (en) * | 1991-04-25 | 1997-08-06 | Brown University Research Foundation | Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products |
JPH05125214A (en) * | 1991-11-01 | 1993-05-21 | Komatsu Ltd | Porous ultrahigh-molecular weight polyethylene and production thereof |
GB9206509D0 (en) * | 1992-03-25 | 1992-05-06 | Jevco Ltd | Heteromorphic sponges containing active agents |
GB9210574D0 (en) * | 1992-05-18 | 1992-07-01 | Ca Nat Research Council | Biotherapeutic cell-coated microspheres for wound/burn and prothesis implant applications |
US5690996A (en) * | 1992-11-02 | 1997-11-25 | Sepragen | Cross-linked cellulose sponge |
US5660857A (en) * | 1993-03-22 | 1997-08-26 | Johnson & Johnson Medical Inc. | Biopolymer composites |
GB2281861B (en) | 1993-09-21 | 1997-08-20 | Johnson & Johnson Medical | Bioabsorbable wound implant materials containing microspheres |
DE9315877U1 (en) | 1993-10-18 | 1994-01-05 | Greenland Gmbh & Co Kg | Haymaking machine |
US6176874B1 (en) * | 1993-10-18 | 2001-01-23 | Masschusetts Institute Of Technology | Vascularized tissue regeneration matrices formed by solid free form fabrication techniques |
CA2115592C (en) * | 1994-02-14 | 1998-09-22 | Kumiko Kimura | Production of glucomannan sponge |
US5834029A (en) * | 1994-07-20 | 1998-11-10 | Cytotherapeutics, Inc. | Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment |
US5891558A (en) * | 1994-11-22 | 1999-04-06 | Tissue Engineering, Inc. | Biopolymer foams for use in tissue repair and reconstruction |
EP0830381A4 (en) * | 1995-06-09 | 2000-11-22 | William N Drohan | Chitin hydrogels, methods of their production and use |
US5965125A (en) * | 1995-10-25 | 1999-10-12 | Transkaryotic Therapies, Inc. | Hybrid matrix implants and explants |
CA2256400A1 (en) * | 1996-05-28 | 1997-12-04 | Brown University Research Foundation | Hyaluronan based biodegradable scaffolds for tissue repair |
GB2318577B (en) * | 1996-10-28 | 2000-02-02 | Johnson & Johnson Medical | Solvent dried polysaccharide sponges |
FI111011B (en) * | 1997-01-15 | 2003-05-15 | Orion Yhtymae Oyj | Solid growth substrate for microorganisms, its production and use |
GB9704749D0 (en) * | 1997-03-07 | 1997-04-23 | Univ London | Tissue Implant |
DK0991705T3 (en) * | 1997-03-31 | 2004-01-12 | Univ Michigan Technology Man W | Open-traced, biodegradable matrices |
US6471993B1 (en) * | 1997-08-01 | 2002-10-29 | Massachusetts Institute Of Technology | Three-dimensional polymer matrices |
-
1996
- 1996-05-22 IL IL11837696A patent/IL118376A0/en unknown
-
1997
- 1997-05-21 DK DK97920932T patent/DK0901384T3/en active
- 1997-05-21 EP EP97920932A patent/EP0901384B1/en not_active Expired - Lifetime
- 1997-05-21 US US09/180,970 patent/US6425918B1/en not_active Expired - Lifetime
- 1997-05-21 DE DE69724780T patent/DE69724780T2/en not_active Expired - Lifetime
- 1997-05-21 JP JP09541956A patent/JP2000512666A/en active Pending
- 1997-05-21 PT PT97920932T patent/PT901384E/en unknown
- 1997-05-21 CA CA2256327A patent/CA2256327C/en not_active Expired - Lifetime
- 1997-05-21 AU AU27117/97A patent/AU714647B2/en not_active Expired
- 1997-05-21 AT AT97920932T patent/ATE249251T1/en active
- 1997-05-21 WO PCT/IL1997/000161 patent/WO1997044070A1/en active IP Right Grant
- 1997-05-21 ES ES97920932T patent/ES2206707T3/en not_active Expired - Lifetime
-
1999
- 1999-10-13 US US09/416,911 patent/US6334968B1/en not_active Expired - Lifetime
-
2001
- 2001-10-23 US US10/004,467 patent/US6793675B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US20030078672A1 (en) | 2003-04-24 |
US6334968B1 (en) | 2002-01-01 |
DK0901384T3 (en) | 2004-01-19 |
CA2256327C (en) | 2012-07-24 |
WO1997044070A1 (en) | 1997-11-27 |
EP0901384A1 (en) | 1999-03-17 |
AU714647B2 (en) | 2000-01-06 |
US6425918B1 (en) | 2002-07-30 |
DE69724780T2 (en) | 2004-07-15 |
ES2206707T3 (en) | 2004-05-16 |
AU2711797A (en) | 1997-12-09 |
ATE249251T1 (en) | 2003-09-15 |
DE69724780D1 (en) | 2003-10-16 |
JP2000512666A (en) | 2000-09-26 |
EP0901384B1 (en) | 2003-09-10 |
IL118376A0 (en) | 1996-09-12 |
US6793675B2 (en) | 2004-09-21 |
PT901384E (en) | 2004-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2256327A1 (en) | Polysaccharide sponges for cell culture and transplantation | |
CN108084461B (en) | Controllable self-crosslinking thiolated hyaluronic acid-collagen composite hydrogel and preparation method and application thereof | |
Kuo et al. | Ionically crosslinked alginate hydrogels as scaffolds for tissue engineering: Part 1. Structure, gelation rate and mechanical properties | |
CN102688525B (en) | Bio-macromolecular hydrogel and preparation method thereof | |
Patel et al. | Poly (ethylene glycol) hydrogel system supports preadipocyte viability, adhesion, and proliferation | |
CN103877617B (en) | Two cross-linked hydrogel of injectable fibroin protein-alginate and preparation method thereof and using method | |
JP6821583B2 (en) | Cartilage gel for cartilage repair containing chitosan and chondrocytes | |
Thornton et al. | Shape-defining scaffolds for minimally invasive tissue engineering | |
CN111588913A (en) | Self-crosslinking hyaluronic acid and hydrogel injection of composite collagen thereof and application of hydrogel injection | |
WO2009154344A1 (en) | Preparation method for natural porous hyaluronic acid-collagen polymer support for tissue repair | |
CN101053679B (en) | Method for preparing polymer multiporous holder filled with fiber protein gel | |
Ullah et al. | Development of various composition multicomponent chitosan/fish collagen/glycerin 3D porous scaffolds: Effect on morphology, mechanical strength, biostability and cytocompatibility | |
JP4753525B2 (en) | Tissue regeneration substrate, transplant material, and production method thereof | |
CN101824160A (en) | Preparation method of chitosan/polyvinyl alcohol/polylactic acid blended porous membrane | |
CN100594949C (en) | Method for producing compound frame of injection type polyester micro-carrier and fibrin gel | |
CN112587726B (en) | Composite hydrogel stent and preparation method and application thereof | |
Liu et al. | Boron-assisted dual-crosslinked poly (γ-glutamic acid) hydrogels with high toughness for cartilage regeneration | |
US20030119157A1 (en) | Macroporous chitosan beads and preparation method thereof | |
CA2274661A1 (en) | Improved hydrogel for tissue engineering | |
KR100891373B1 (en) | Preparation method of porous hyaluronic acid sponge for cell delivery system | |
WO2007129828A1 (en) | Preparation method of porous hyaluronic acid sponge for cell delivery system | |
CN100402097C (en) | Skin wound repairing agar/collagen dressing and its prepn and application | |
CN111991620A (en) | Submucosal injection solution composition for endoscope and preparation method thereof | |
Chandy et al. | The development of porous alginate/elastin/PEG composite matrix for cardiovascular engineering | |
CN114438013A (en) | Method for preparing cell culture meat biological scaffold through physical crosslinking |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20170523 |